Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10205067 | 0.93 | POLB (0.48) | L3MBTL1TSHRCYP2D6HRH3ALDH1A1 | |
| SCHEMBL26140448 | 0.93 | L3MBTL1 (0.47) | L3MBTL1TSHRCYP2D6HRH3ALDH1A1 | |
| SCHEMBL16072925 | 0.90 | TSHR (0.47) | L3MBTL1TSHRCYP2D6HRH3ALDH1A1 | |
| SCHEMBL16992001 | 0.89 | MAPK1 (0.49) | L3MBTL1TSHRALDH1A1RAB9ACYP3A4 | |
| SCHEMBL21569681 | 0.87 | L3MBTL1 (0.43) | L3MBTL1TSHRCYP2D6HRH3ALDH1A1 | |
| SCHEMBL20348488 | 0.85 | TSHR (0.42) | L3MBTL1TSHRCYP2D6HRH3ALDH1A1 | |
| SCHEMBL18745343 | 0.84 | TSHR (0.43) | L3MBTL1TSHRCYP2D6HRH3ALDH1A1 | |
| SCHEMBL2146500 | 0.83 | ALDH1A1 (0.48) | L3MBTL1TSHRALDH1A1RAB9ACYP3A4 | |
| SCHEMBL2146495 | 0.83 | ALDH1A1 (0.48) | L3MBTL1TSHRALDH1A1RAB9ACYP3A4 | |
| SCHEMBL16072922 | 0.83 | KDM5A (0.47) | L3MBTL1TSHRRAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233435-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2019-08-01 | — | — | US | disclosed |
| US-10227359-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180222920-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2018-08-09 | — | — | US | disclosed |
| US-9834565-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170158710-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227359-B2 | Tricyclic heterocycles as bet protein inhibitors | BRD3, BRD1, BRD2 | L3MBTL1 517/4885TSHR 1954/4885CYP2D6 3918/4885 |
| US-20190233435-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD3, BRD1, BRD2 | L3MBTL1 517/4885TSHR 1954/4885CYP2D6 3918/4885 |
| US-20170158710-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD3, BRD1, BRD2 | L3MBTL1 517/4885TSHR 1954/4885CYP2D6 3918/4885 |
| US-20180222920-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD3, BRD1, BRD2 | L3MBTL1 517/4885TSHR 1954/4885CYP2D6 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.